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evidence of their ability to prevent or delay cognitive decline in AD is still lacking. Each vitamin E
form is functionally unique and shows specific biological functions. Tocotrienols seem to have supe-
rior antioxidant and anti-inflammatory properties compared with tocopherols.
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inconsistent findings from observational studies and the methodological limitations of clinical trials.
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In 1922, Evans and Bishop [1] first described a “sub-
stance X,” lately defined as vitamin E, as a crucial factor
for fertility and reproduction in female rats. Thus, vitamin
E was scientifically named as tocopherol from the Greek
word tokos meaning childbirth, phero meaning to bring
forth, and ol ending to indicate the alcohol properties. Since
its discovery, vitamin E has been extensively studied to bet-
ter understand its role in different pathophysiological condi-
tions [2–4]. Most of the data, so far available, are mainly
focused on vitamin E lipid-soluble antioxidant activity,
thanks to its ability to quench or neutralize excess radicals
[5]. However, vitamin E, including eight compounds, claims
also several biological roles unrelated to antioxidant proper-
ties, being regulators of gene expression and signal transduc-thor. Tel.:139 075 5783270; Fax:139 075 5783878.
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).tion and modulators of cell functions via interaction with
specific membrane domains. Thus, the vitamin E family
has many and complex biological activities and pleiotropic
effects [6–10].
The introduction of the free radical theory to explain the
pathophysiology of brain aging and neurodegenerative dis-
eases, such as Alzheimer’s disease (AD), has propelled a
great interest in this vitamin. The theory posits that reactive
oxygen species (ROS) and reactive nitrogen species (RNS)
are responsible for oxidative and/or nitrosative modifica-
tions of several biological molecules and that accumulation
of free radical–mediated damage to neuronal components,
along with other age-related changes, is one of the main
causes of neurodegeneration [11]. As a result, preventing
or minimizing oxidative and/or nitrosative stress may coun-
teract the molecular basis of pathological brain aging and
subsequent neurodegeneration leading to brain damage, sug-
gesting that vitamin E might be an important preventive and
therapeutic strategy.imer’s Association. This is an open access article under the CC BY-NC-ND
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regarding the biological properties of vitamin E and the po-
tential therapeutic and/or preventive role that this natural di-
etary factor plays in AD.2. Methods
A literature search in PubMed, Medline, and Cochrane
[12] databases of articles published with the medical subject
heading keywords “Vitamin E,” “Vitamin E and Alzheimer’s
Disease,” “Vitamin E and cognition,” “Vitamin E, cognition
and aging,” “Vitamin E, cognition and AD,” and “Vitamin E
trial” has been carried out. The keywords were used in all
possible combinations to retrieve the maximal number of ar-
ticles. All types of studies, from bench and animal models to
clinical, were included.3. Results
3.1. Vitamin E family: Metabolism and biological
properties
The term “vitamin E” refers to a family of eight naturally
occurring homologues that are synthesized by plants from
homogentisic acid. It includes four tocopherols and four to-
cotrienols. Tocopherols and tocotrienols are subdivided
into a, b, g, and d forms based on the methyl and hydroxyl
substitution in their phenolic rings. a-Tocopherol is the
most abundant form found in nature and, at present, the
most widely studied [13]. The prevalent sources of vitamin
E are vegetable oils, nuts, and seeds, containing all four
tocopherol and tocotrienol congeners (a, b, g, and d) in
different proportions. Common food sources of a-tocopherol
are almonds, avocados, hazelnuts, peanuts, and sunflower
seeds; of b-tocopherol oregano and poppy seeds; of g-
tocopherol pecans, pistachios, sesame seeds, and walnuts;
and of d-tocopherol edamame and raspberries. Tocotrienols
are differentiated from tocopherols by the degree of satura-
tion at the side chains having three double bonds at carbons
3, 7, and 11, whereas tocopherols possess saturated phytyl
side chains. Tocotrienols prevail in rice bran, barley, oats,
and palm oil [13]. Other sources of tocotrienols include grape
fruit seed oil, oats, hazelnuts, maize, olive oil, Buckthorn
berry, rye, flax seed oil, poppy seed oil, and sunflower oil.
Plasma concentration of vitamin E depends on absorp-
tion, tissue delivery, and excretion rate. Because all forms
of vitamin E are lipid soluble, they are easily absorbed
from the intestinal lumen after dietary intake via micelles
created by biliary and pancreatic secretions. Vitamin E is
then incorporated into chylomicrons and secreted into the
circulation where, transported by various lipoproteins, it rea-
ches the liver. Unlike tocopherols, which were distributed
equally in all the lipoprotein fractions, tocotrienols are
mainly detected in the high-density lipoprotein cholesterol.
The estimated a-tocopherol half-life in plasma of healthy in-
dividuals ranges from 48 to 60 hours, which is much longerthan the half-life of g-tocopherol (roughly 15 hours). These
kinetic data underscore the interesting concept that whereas
a-tocopherol levels are maintained, the other forms of
vitamin E are removed quite rapidly. Thus, a-tocopherol is
regarded as the predominant form to be accumulated in tis-
sues, where other vitamin E congeners are quickly metabo-
lized to carboxychromanols, hydroxycarboxychromanol,
and carboxyethylhydroxychroman (for tocotrienols) deriva-
tives. Although the pharmacokinetics of tocotrienols are
distinctly different from tocopherols, biodistribution study
showed considerable accumulation of tocotrienols in periph-
eral tissues, such as bones, brain, lung, muscle, and skin.
Vitamin E supplements mostly contain a-tocopherol, for
which the current recommended dietary allowance is
15 mg/day. A tolerable upper intake level (UL) for any
form of supplemental a-tocopherol has been established
by the Food and Nutrition Board of the Institute of Medicine
to avoid potential side effects. Specifically, the UL of
1000 mg/day of a-tocopherol in any supplemental form cor-
responds to the highest dose unlikely to result in hemorrhage
in almost all adults. The safe dose of various tocotrienols for
human consumption is estimated to be 200–1000 mg/day.
Because of possible interference, it is recommended for to-
cotrienols to be taken approximately 6 hours apart from
tocopherol-containing supplements [14].
All forms of vitamin E meet the chemical definition of an
antioxidant moiety: “chain-breaking free radical scavenger,”
as demonstrated in conventional in vitro systems. Oxidative
stress, defined as the imbalance between generation of reac-
tive species and antioxidant defense, leads to damage of
DNA and of proteins and lipids and it is thought to be involved
in the pathogenesis of AD [15–17]. Vitamin E is widely
accepted as one of the most potent antioxidant in nature, but
hints for this function in vivo are scarce. The antioxidant
property is related to the hydroxyl group of the aromatic
ring of tocochromanols, which donates hydrogen to
neutralize free radicals, such as ROS. The antioxidant
activity of a, b, and g isoforms of both tocopherol and
tocotrienol is similar, except the d isoform that has weaker
activity [18,19]. Underscoring the importance of viewing
vitamin E as a family is the evidence that g-tocopherol and
tocotrienols claim functions different from those of a-
tocopherol. In fact, g-tocopherol appears to be more
efficient compared with a-tocopherol in increasing
superoxide dismutase activity in plasma and in tissues [20].
Importantly, many studies have demonstrated the superiority
of a tocotrienol over a-tocopherol in neutralizing the peroxyl
radicals and lipid peroxidation, as shown in rat liver, whereas
g-tocotrienol elicited stronger protective effect against oxida-
tive damage in brain mitochondria (reviewed in Brigelius-
Flohe [18]). Being themain lipid-soluble antioxidant, vitamin
E has a prominent role in protecting cellular membranes,
which could be crucial in mitochondria, the main source
and elective target of free radicals. Whether the antioxidant
potential of vitamin E family is used in vivo for protection
against oxidative damage is still an open question. In fact,
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able to disclose the antioxidant effects of tocopherols in vivo.
However, vitamin E biological activity is not limited to
antioxidant properties. In fact, vitamin E forms are involved
in the regulation of inflammatory response, modulation of
cellular signaling, membrane-bound enzymes, gene expres-
sion, cell proliferation, and several molecular pathways (re-
viewed in Brigelius-Flohe [18]). For example, a-tocopherol
inhibits the activation of the protein kinase C by preventing
its phosphorylation and its localization to the membrane.
a-Tocopherol was shown to enhance the protein phosphatase
2A (PP2A) activity, an enzyme that is implicated in AD path-
ophysiology [21]. Vitamin E regulates the expression of spe-
cific genes not only related to oxidative stress but also
involved in cholesterol homeostasis, inflammatory path-
ways, and cellular trafficking, including of synaptic vesicular
transport and neurotransmitter release. Genes found to be
regulated by a-tocopherol include those encoding proteins
involved in apoptosis (CD95L and Bcl2-L1), cell cycle regu-
lation (p27, cyclin D1, and cyclin E), cell adhesion (E-selec-
tin, L-selectin, ICAM-1, VCAM-1, and integrins), cell
growth (CTGF), extracellularmatrix formation and/or degra-
dation (glycoprotein IIb, MMP-1, andMMP-19), lipoprotein
receptors (CD36, SR-BI, SR-AI/II, and LDL receptor),Table 1
Biological properties of tocopherols and tocotrienols
Vitamin E forms Biological properties (putative mechanisms)
Tocopherols  All forms
- Antioxidant (increase in the activity of antioxidant enzym
 a-Tocopherol
- Anti-inflammatory activity (IL-6, CRP, and VEGF reduc
- Modulation of cell proliferation and differentiation (PKC
- Regulation of bone remodeling
- Neuroprotective (PP2A modulation)
 g-Tocopherol
- Anti-inflammatory activity (modulation of cytokines exp
- Anti-neoplastic activity (modulation of signal transductio
 d-Tocopherol
- Antineoplastic activity (modulation of signal transductio
Tocotrienols  All forms
- Antioxidant (increase in the activity of antioxidant enzym
- Cholesterol-lowering activities (inhibition of HMG-CoA
- Anti-inflammatory activity (suppression of NF-kB, TNF
- Antineoplastic activity (activation of caspases)
 a-Tocotrienol
- Immunostimulatory (induction of antibody and IFN-g, IL
- Antineoplastic activity (suppression of HMGR activity a
- Neuroprotective (inhibition of PP 60 [c-Src] kinase activ
 g-Tocotrienol
- Antineoplastic activity (inhibition of NF-kB, TGF-b, and
downregulation of Bcl-2 and cyclin D; suppression of H
- Neuroprotective (inhibition of 12-lipoxygenase activity)
 d-Tocotrienol
- Anti-neoplastic activity (induction and potentiation of ap
- Immunostimulatory (suppression of TNF-a)
Abbreviations: CRP, C-reactive protein; HMG-Co A, hydroxy-methylglutaryl co
interferon; Inos, inducible nitric oxide synthase; MAP, mitogen activated protein;
phosphoinositide 3; PKC, protein kinase C; PP2A, protein phosphatase 2A; TGF, t
thelial growth factor.inflammation (IL-1b, IL-2, IL-4, and TGF-b), transcriptional
control (PPARg), metabolism (CYP3A4, HMG-CoA reduc-
tase, and g-glutamylcysteine synthetase), and other pro-
cesses (leptin and b-secretase in neurons) [22]. Each
vitamin E form is functionally unique and shows specific bio-
logical functions as summarized in Table 1. In summary, to-
cotrienols seem to have superior antioxidant and anti-
inflammatory properties over a-tocopherol, and the potential
neuroprotective role of vitamin E family can be explained by
biological properties other than the antioxidant activity.3.2. AD pathogenesis: A role for vitamin E
AD is a neurodegenerative disorder associated with aging
and characterized by progressive memory loss and cognitive
deterioration. Among the hypothetical mechanisms involved
in the cognitive decline and AD pathogenesis, are the
increased oxidative stress and inflammation that may ulti-
mately lead to neuronal death. The polyunsaturated fatty acids
ofmembrane lipids are themain targets for ROS and peroxide
radicals, which make the brain particularly vulnerable to
oxidative damage. In patients with AD, concentrations of ma-
londialdehyde, a measure of lipid peroxidation, are indeed
significantly elevated [23]. Moreover, neurons are sites ofes and quenching and scavenging of free radicals)
tion)
inhibition, MAP kinase, and PI3 kinase activation)
ression: IL-6, CRP, and VEGF reduction)
n, apoptosis, and cell proliferation)
n, apoptosis, and cell proliferation)
es and quenching and scavenging of free radicals)
reductase activity)
-a, IL-1, IL-6, IL-8, iNOS, and Cox2)
-4, and IL-1b production)
nd inhibition of angiogenesis)
ity, phosphorylation of Erk, and inhibition of 12-lipoxygenase activity)
P38 signalling pathways; induction and potentiation of apoptosis;
MGR activity; and inhibition of cell proliferation through cell cycle arrest)
optosis and inhibition of cell proliferation through cell cycle arrest)
enzyme A; HMGR, hydroxy-methylglutaryl reductase; IL, interleukin; INF,
NF-kb, nuclear factor kappa-light-chain-enhancer of activated B cells; PI3,
umor growth factor; TNF a, tumor necrosis factor a; VEGF, vascular endo-
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tion of amyloid b (Ab) is a constant feature in the brains of pa-
tients with AD, which leads directly to increased free radical
formation and indirectly stimulating inflammatory cells (mi-
croglia) to produce prooxidant species, including reactive ni-
trogen intermediates. Some studies also indicate that vitamin
E status is altered in ADwhere an increased concentrations of
vitamin E in the brains and decrease in plasma of AD patients
have been observed, suggesting a possible compensatory
response to oxidative damage [24]. Although it remains an
open question what initiates and propagates oxidative stress
inAD,multiple antioxidant strategies have been tried in recent
decades to assess potential beneficial effects against AD onset
and/or progression. Vitamin E is able to decrease lipid perox-
idation susceptibility by 60% in AD patients compared with
controls [25]. Postmortem analysis of cerebrospinal fluid
also reveals that a-tocopherol levels positively correlate
with perceptual speed and AD pathology in patients [26].
Application of vitamin E in rat neuronal cultures prevents
Ab-associated ROS from forming and decreases oxidative
stress markers [27].
The inflammatory pathways also seem to be involved in
AD pathogenesis [28], and some vitamin E forms exhibit
strong anti-inflammatory properties. Increased levels of
proinflammatory cytokines (such as IL-1, IL-6, and TNF-
a) have been detected in brain tissue and cerebrospinal fluid
of patients with AD. Both TNFa and IL-1 can then increase
expression of amyloid precursor protein and Ab peptide
[28]. Thus, it is reasonable to hypothesize that anti-
inflammatory agents, including vitamin E, might reduce
the probability of developing AD or slow its progression.
Modulation of cellular signaling can also be relevant for
neuroprotection. Interestingly, studies conducted in rats
demonstrated that in the hippocampus, vitamin E depriva-
tion is associated with the expression of a number of genes
linked to the onset and progression of AD. These genes
were then identified as important regulators of hormone
metabolism, apoptosis, growth factors, neurotransmission,
and Ab metabolism [29]. Concordantly, further studies
showed that low a-tocopherol levels in the brain induce
downregulation of genes involved in myelination and synap-
togenesis, neuronal vesicle transport, and glial functions
[30]. A more recent study, based on both in vitro and
in vivo experiments, using animal models mimicking the hu-
man vitamin E deficiencies, confirmed a mechanism by
which vitamin E protects against the formation of hyper-
phosphorylated tau, a well-established biomarker of AD
through the inhibition of p38MAPK, whose activity is essen-
tial for phosphorylation of neuronal tau molecules [31].
Indeed, vitamin E and related tocopherols and tocotrie-
nols inhibit several AD-relevant enzymes, which include
COX2, implicated in neuroinflammation, oxidative damage,
and the development of AD pathology [32–34]. Moreover,
vitamin E activates PP2A, a phosphatase that plays a
significant role in tau homeostasis and has been shown to
be downregulated in human AD brains [21]. Thus, vitaminE, combining all the described activities, may exert preven-
tive and therapeutic effects in AD pathogenesis.3.3. Vitamin E, cognitive performance, and AD: The
evidence from observational studies
Several studies investigated the association between
vitamin E serum levels and cognitive performance
(Table 2). The importance of adequate nutrition in support
of healthy brain function was first described in the 1980s,
when it was demonstrated as a direct link between nutri-
tional status and cognitive performances. In old age subjects
(over 60 years), a positive relationship between cognitive
performance and plasma nutrient concentrations (including
folate, vitamin B12, and vitamin C) was found [35]. Later,
a study involving a multiethnic population in the United
States showed that memory performances were linked to
vitamin E and not to vitamin C and b-carotene. Precisely,
poor memory performance was consistently evident when
low plasma levels of vitamin E were detected [36]. Further
evidence emphasize the positive role of vitamin E in brain
healthy function, when high levels of a-tocopherol have
been found in plasma of cognitively normal centenarians
[37,38], what suggests the beneficial property of vitamin E
on cognition. Finally, another evidence of a positive
association between vitamin E status and cognitive
function was found in a small study including cognitively
healthy elderly subjects. Subjects with vitamin E intakes
less than 50% of the recommended daily intake showed
worse cognitive performances compared with subjects
with a higher intake [39]. In general, no consistent results
from supplements intake were found, whereas many studies
on intake from food showed reduced risk of cognitive
decline and/or AD.
Based on these strong evidences, several studies evalu-
ated the association between vitamin E and AD. A study
by Engelhart et al. [40] showed a lower risk of developing
AD in individuals consuming food with a high content of
vitamin E and C (vitamin E .15 mg/day) and followed for
a period of 6 years. Dietary intake was assessed by means
of a validated semiquantitative food frequency question-
naire. A further study conducted in Italy and involving
1033 elderly subjects supported the notion that higher
vitamin E plasma levels might provide significant protection
against cognitive impairment and dementia [41]. Ravaglia
et al. [42] measured baseline plasma tocopherols and their
oxidation markers in 761 elderly Italian subjects from a
population-based cohort and demonstrated that plasma con-
centrations of some non-a-tocopherol forms of vitamin E are
associated with cognitive impairment in elderly people. The
preventive effect of vitamin E with respect to developing AD
symptoms was confirmed in a more recent study on cogni-
tively healthy subjects [43]. In this study, Mangialasche
et al. [43] investigated the association between plasma levels
of all eight forms of vitamin E family and incidence of AD
among oldest-old individuals (over 80 years) followed up to
Table 2
Vitamin E, cognitive function, and AD: an overview of observational studies
Study Population Vitamin E measure Results
Perkins et al.
(1999)
4809 Non-Hispanic White, non-Hispanic Black, and
Mexican-American elderly
Plasma a-tocopherol Decreasing serum levels of vitamin E were
consistently associated with increasing levels of
poor memory after adjustment for multiple
covariates
K1apcinska
et al. (2000)
Sixteen centenarians (1 male and 15 female subjects
aged 101–105 years) living in the Upper Silesia
district (Poland)
Plasma a-tocopherol In comparison with young healthy female adults, the
centenarians had significantly higher red blood
cell glutathione reductase and catalase activities
and higher, although insignificantly, serum
vitamin E level
Ortega et al.
(2002)
A group of 34 men and 86 women, aged 65–91 years,
cognitively healthy
Plasma a-tocopherol This study shows a relationship between vitamin E
status and cognitive function
Engelhart et al.
(2002)
A total of 5395 participants who, at baseline, were
aged at least 55 years, free of dementia,
noninstitutionalized, and had reliable dietary
assessment
Plasma a-tocopherol After a mean follow-up of 6 years, high dietary intake
of vitamin E may lower the risk of AD
Cherubini
et al. (2005)
A population-based cohort study conducted in Italy.
A total of 1033 participants aged at least 65 years
Plasma a-tocopherol This study supports the notion that higher vitamin E
plasma levels might provide significant protection
against cognitive impairment and dementia in
elderly subjects
Ravaglia et al.
(2008)
761 Elderly Italian subjects from a population-based
cohort assessed in 1999–2000 for MCI and
dementia
Plasma a, b, g, d-
tocopherol, a-TQ, and
5NGT
Plasma concentrations of some non-a-tocopherol
forms of vitamin E are associated with cognitive
impairment in elderly people
Mangialasche
et al. (2010)
A dementia-free sample of 232 subjects aged 801
years, derived from the Kungsholmen Project,
followed for 6 years
a, b, g, d-tocopherol, a, b,
g, d-tocotrienol, a-TQ,
and 5NGT in plasma
High plasma levels of vitamin E are associated with a
reduced risk of AD in advanced age. The
neuroprotective effect of vitamin E seems to be
related to the combination of different forms,
rather than to a-tocopherol alone
Mangialasche
et al. (2012)
168 AD cases, 166 MCI, and 187 cognitively normal
people from the longitudinal multicenter
AddNeuroMed study
a, b, g, d-tocopherol, a, b,
g, d-tocotrienol, a-TQ,
and 5NGT in plasma
Low plasma tocopherols and tocotrienols levels are
associated with increased odds of MCI and AD
Mangialasche
et al. (2013)
81 Patients with AD, 86 with MCI, and 86 control
individuals were enrolled from the longitudinal
multicentre AddNeuroMed study
a, b, g, d-tocopherol, a, b,
g, d-tocotrienol, a-TQ,
and 5NGT in plasma
Plasma levels of tocopherols and tocotrienols
together with automated MRI measures can help
to differentiate AD and MCI patients from control
subjects and to prospectively predict MCI
conversion into AD
Mangialasche
et al. (2013)
Sample of 140 noncognitively impaired elderly
subjects derived from the CAIDE study and
followed up for 8 years
a, b, g, d-tocopherol, a, b,
g, d-tocotrienol, a-TQ,
and 5NGT in plasma
Elevated levels of tocopherol and tocotrienol forms
are associated with reduced risk of cognitive
impairment in older adults
Abbreviations: AD, Alzheimer’s disease; CAIDE, Cardiovascular Risk Factors, Aging, and Dementia; MCI, mild cognitive impairment; MRI, magnetic reso-
nance imaging; a-TQ, a-tocopherylquinone; 5NGT, 5-nitro-g-tocopherol.
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levels of total tocopherols, total tocotrienols, or total vitamin
E had a reduced risk of developing AD in comparison with
those with lower levels. Most importantly, this study sug-
gested that the neuroprotective effect of vitamin E was
related to the combination of the different forms, rather
than to a-tocopherol alone. The same research group re-
ported similar observations with a study showing that low
plasma tocopherols and tocotrienols were associated with
increased odds of MCI and AD diagnosis, in a European
multicenter study gathering 521 individuals [44]. With a
more recent study, it has been demonstrated that plasma
levels of tocopherols and tocotrienols together with auto-
mated magnetic resonance imaging measures can help to
differentiate AD and MCI patients from cognitively healthy
subjects and to prospectively predict MCI conversion into
AD [45]. Indeed, elevated levels of tocopherol and tocotrie-nol forms were found to be associated with a reduced risk of
cognitive impairment in a cohort of older adults derived
from the Cardiovascular Risk Factors, Aging, and Dementia
study and followed up for 8 years [46].3.4. Vitamin E, cognitive decline, and AD: The evidence
from population-base prospective studies
The relationship of vitamin E dietary or supplemental
intake with the risk of cognitive decline and AD has been
investigated also in different population-base prospective
studies, including self-selected vitamin supplementation
and randomized placebo-controlled studies (Table 3). After
dietary supplementation (including vitamins C, E, and thia-
mine), La Rue et al. [47] described a positive association be-
tween nutritional status and cognitive performance in an
elderly (aged 66–90 years) sample of community residents.
Table 3
Vitamin E, cognitive function, and AD: an overview of population-base prospective studies
Study Population and follow-up Outcome Vitamin E source Results
Self-selected
vitamin
supplements
La Rue et al.
(1997)
137 Elderly (aged 66–90 years) community
residents followed for 6 years
Cognition Dietary
supplementation
Use of self-selected vitamin supplements is
associated with better performance
Morris et al.
(2002)
2889 Community residents, aged 65–102 years
followed for 3 years
Cognition Dietary and
supplements
Vitamin E intake, from foods or supplements,
is associated with less cognitive declinewith
age
Grodstein et al.
(2003)
14,968 Community-dwelling women who
participated in the Nurses’ Health Study
followed for 15 years
Cognition Supplements The use of specific vitamin E supplements is
related to modest cognitive benefits in older
women
Zandi et al.
(2004)
3227 Elderly (65 years or older) residents of
Cache County
AD Supplements Use of vitamin E and vitamin C supplements in
combination is associated with reduced
prevalence and incidence of AD
Randomized
controlled
studies
Sano et al. (1997) Double-blind, placebo-controlled,
randomized, multicenter trial in 341 patients
with AD followed for 2 years
AD Supplementation (a-
tocopherol 2000 IU
a day)
In patients with moderately severe impairment
from AD, treatment with a-tocopherol
slows the progression of disease
Petersen et al.
(2005)
A double-blind study, including 769 subjects
with the amnestic subtype of MCI followed
for 3 years. Subjects were randomly
assigned to receive vitamin E daily,
donepezil daily, or placebo
AD Supplementation
(2000 IU of a-
tocopherol daily)
Vitamin E has no benefit in patients with MCI
Kang et al.
(2006)
6377 Women 65 years or older from the
Women’s Health Study and followed for
10 years
Cognition Supplementation (600
IU a-tocopherol
acetate, on alternate
days)
Long-term use of vitamin E supplements do
not provide cognitive benefits among
generally healthy older women
Lloret et al.
(2009)
57 AD patients were recruited and divided in 2
groups: placebo or treated with vitamin E
per day for 6 months
Cognition
AD
Supplementation (800
IU of a-tocopherol
per day)
Vitamin E lowers oxidative stress in some AD
patients and maintains cognitive status;
however, in those in which vitamin E does
not prevent oxidative stress, it is detrimental
in terms of cognition
Dysken et al.
(2014)
Double-blind, placebo-controlled, parallel
groups, randomized clinical trial involving
613 patients with mild to moderate AD
followed for 5 years
Functional
status
Supplementation
(2000 IU of a-
tocopherol daily)
Vitamin E supplementation results in slower
functional decline
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment.
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number of healthy people (aged 65–102 years) over a period
of 3 years in the presence of high and low antioxidant con-
sumption. Diet was assessed using a modified Harvard
self-administered food frequency questionnaire that
measured usual consumption during the past year of several
food items and vitamin supplements. Results revealed a
reduced cognitive decline per year in individuals with higher
vitamin E intake (obtained by diet and from supplements)
compared with subjects with low vitamin E intake [48]. In
a larger study, Grodstein et al. [49] analyzed the cognitive
performances of women aged 70–79 years after vitamin E
and C supplementation for 15 years. Daily doses of vitamin
E were determined by using the ranges reported from admin-
istrated questionnaires. They defined a very high dose of
vitamin E as 600 mg. Results showed that users of supple-
ments had significantly better cognitive performances than
nonusers and that in the long-term users (.10 years), theeffect of consuming vitamin E and C was equivalent, in
cognitive performances, to being 1.5 years younger. Impor-
tantly, although the intake of vitamins E and C alone showed
little evidence of improving the cognitive capacities of users,
their combination was necessary to obtain significant effects
[49]. In fact, vitamins C and E support each other’s antioxi-
dant function. Whereas vitamin E acts as an antioxidant and
requires regeneration after it “heals” free radical damage
before it can function properly again, the vitamin C, working
as a potent reducing agent, is able to restore vitamin E’s anti-
oxidant function so that it can continue to fight tissue dam-
age. Indeed, another study further supported that the use of
vitamins E and C supplements in combination is associated
with reduced prevalence and incidence of AD among elderly
subjects [50].
Taken together, these studies demonstrate that consump-
tion of vitamin E is linked to improved cognitive perfor-
mance in humans. In light to such evidences, clinical trials
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patients with AD. One of the first randomized controlled tri-
als (RCTs) treated patients suffering from severe AD with
selegiline and vitamin E (a-tocopherol 1000 IU twice per
day) for 2 years [51]. Vitamin E supplementation signifi-
cantly delayed decline in daily life activities and reduced
needs for care. However, no improvements on cognitive
test scores were observed in this study, maybe because of
the relatively advanced severity of AD in this population.
The results associated with vitamin E supplementation in pa-
tients with severe AD prompted investigating if similar ef-
fects that are even more beneficial could also be obtained
in early stages of AD or, better, in prodromic phase such
as mild cognitive impairment (MCI). To this purpose, Pe-
tersen et al. [52] enrolled subjects with amnestic MCI
from the Alzheimer’s Disease Cooperative Study, who was
treated with 2000 IU/day of vitamin E or placebo for 3 years.
This study failed to demonstrate any significant difference in
the progression fromMCI to AD after vitamin E supplemen-
tation. No unexpected side effects were observed after
vitamin E treatment. A substudy of the Women’s Health
Study, a double-blinded, placebo-controlled, randomized
trial of vitamin E supplementation with a 10-year duration
that aimed at evaluating the cognitive performance of a large
number of elderly healthy women randomized to receive
vitamin E (a-tocopherol acetate) 600 IU every other day
with a follow-up period of 4 years, showed that compared
with the placebo group, the vitamin E group did not have a
lower risk of substantial cognitive decline [53]. However,
this study showed fewer adverse cognitive changes when
the vitamin E group was compared with the placebo group
with dietary intake of vitamin E below the median of
6.1 mg/day. Interestingly, beneficial effects (measured by
the absence of cognitive decline over time) after vitamin E
supplementation were observed in another AD cohort [54].
Importantly, in this case, the cognitive performance of the
participants was constant over time (and even slightly
improved) only when the vitamin E antioxidant activity
was confirmed to be effective, by measuring blood oxidized
glutathione (GSSG). Conversely, deleterious effects (pro-
nounced loss of cognitive abilities) were present when no
enhanced antioxidant levels were detected [54]. These re-
sults prompted authors to introduce the novel concept of
stratifying AD patients into vitamin E respondents and non-
respondents, based on measures of plasma GSSG, the
oxidized form of the common antioxidant glutathione
(GSH). This study highlights the anti-oxidative properties
of vitamin E as a possible mechanism of action against
AD pathology.
Indeed, the Trial of Vitamin E and Memantine in
Alzheimer’s Disease has been designed to assess, after 5
years, the efficacy of a-tocopherol or memantine or their
combination versus placebo in delaying clinical progression
of AD in patients already taking an acetylcholinesterase
inhibitor [55]. This study included old age subjects withmild-to-moderate AD. The authors found that 2000 IU/day
of a-tocopherol significantly delayed the functional decline
and decreased the caregiver burden, confirming data gener-
ated in the study of Sano et al. [51] on severe AD patients.
Serum concentration of vitamin E at baseline was measured
before randomization and in annual assessments. Cut points
of 1.3-fold or greater increases in a-tocopherol were associ-
ated with a good level of medication adherence. In addition,
favorable effects (but not statistically significant) were asso-
ciated with a-tocopherol treatment when cognitive functions
such as memory and language were considered and also the
time necessary for the caregivers to assist the patients.4. Discussion
4.1. Why vitamin E therapy failed for the treatment of AD?
Despite many individuals take daily vitamin E supple-
ments with the assumption that they may maintain a good
brain health, the role of vitaminE in prevention and treatment
of AD is still unclear and under debate. Two meta-analyses
published in 2005 [56] and in 2007 [57], reporting increased
mortality in subjects taking high dose of vitamin E, ques-
tioned its protective role. However, the meta-analysis pub-
lished by Miller et al. [56] demonstrated that only the
smaller trials showed either an increase or a decrease in all-
cause mortality and that the overall effect was near to zero.
Thus, the difficulty in performing precise and uniform studies
accounts for these conflicting results. On the other hand,
several considerations arise from the fact that vitamin E ther-
apy is ineffective for some or outright detrimental for others.
The data on randomized therapy are very limited and depend
on small patient cohorts. For example, in the study by Lloret
et al. [54], the sample size was very small, vitamin E supple-
mentation included 800 IU/day, as opposed to 2000 IU/day in
the other studies, and the supplementation period was 6
months, whereas in other studies, supplements were given
for approximately 2 to 3 years.
Moreover, the two positive studies, by Dysken et al. [55]
and Sano et al. [51], have weaknesses that should be consid-
ered. In the first one, vitamin E was beneficial only in pa-
tients not receiving memantine therapy compared with
those receiving memantine and a convincing rationale was
lacking. In the second one, there were large differences in
baseline MMSE values between patients receiving placebo
and those receiving vitamin E or selegiline. Consequently,
also selegiline, which is not considered to enhance cognitive
deficits, resulted beneficial. However, an important param-
eter that can influence the outcomes of such studies relates
to the form of administered vitamin E. In these cases, the
same form of vitamin E (DL-a-tocopherol) was used, and
in both, the a-tocopherol status of the subjects was measured
in serum. This uniformity contributes to an easy comparison
of the two studies. This information, however, was not re-
ported in the other reports reviewed, even when the
V. Boccardi et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 182-191 189measurement of the vitamin E levels would have been useful
for a comprehensive understanding of the proposed results.
Another factor complicating direct comparison of the
outcomes on human data is the baseline level of vitamin E.
Several epidemiological studies indicate that vitamin E
from food sources is more effective at preventing age-
related neurodegenerative disorders than supplementation
[58]. This idea is supported by the fact that vitamin E from
food sources usually comprises all tocopherols and tocotrie-
nols, whose properties and possible functions are different
[59]. Although a-tocopherol is the most abundant and
bioavailable form of vitamin E in human tissues, it was
demonstrated that tocotrienols may be more potent radical
scavengers than a-tocopherol under specific experimental
conditions [58,60,61]. Taken together, differences between
RCTs and observational studies could be because of the
varying chemical forms present in the supplements and in
food and their bioavailability. In addition, the combination
of nutrients from food, as seen in observational studies,
may have interactive and synergic effects on health. Such
beneficial effects may be masked or mitigated in
supplementation trials [62].4.2. Conclusions and future directions
About 100 years since the discovery of vitamin E, its
functional roles in the brain still require investigations.
More specifically, in spite of the strong biological plausibil-
ity of a possible neuroprotective activity, the role of the
different forms of vitamin E family in protecting from AD
is still unclear. In recent years, the isolation and identifica-
tion of various forms of tocopherols and tocotrienols and
the consideration of vitamin E as a family have been strongly
impacted in the effort to establish biological effects behind
the primary role as an antioxidant. Most studies have
focused on a-tocopherol, and few studies have examined
all eight natural vitamin E forms in relation to cognitive
decline and/or AD.
Experiments with vitamin E in vitro and in animal models
support the role of this molecule in mitigating the effects of
AD pathology. Most of the human observational epidemio-
logical studies in general are consistent with the hypothesis
that there is an inverse correlation between vitamin E levels
and/or intake and decline in cognitive functions and risk to
develop dementia. In sharp contrast, randomized clinical tri-
als with vitamin E apparently do not fully support this evi-
dence. More research aimed at defining the uses and the
dosage of different tocopherols and tocotrienols in prospec-
tive interventional studies is warranted for conclusive re-
sults.Acknowledgments
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1. Systematic review: A literature search in PubMed,
Medline, and Cochrane databases of all articles pub-
lished with the medical subject heading keywords
“Vitamin E,” “Vitamin E and Alzheimer’s Disease,”
“Vitamin E and cognition,” “Vitamin E, cognition
and aging,” and “Vitamin E, cognition and AD” has
been carried out. The keywords were used in all
possible combinations to retrieve the maximal num-
ber of articles. All types of study designs were
included.
2. Interpretation: The exact role in pathogenesis and the
benefit of vitamin E as treatment for Alzheimer’s dis-
ease (AD) is still under debate. In this review, we
focus on the most important studies that have
contributed to clarifying such aspects.
3. Future directions: More research aimed at defining
the use and the dosage of different tocopherols and
tocotrienols in prospective interventional studies is
warranted to better clarify the role of vitamin E fam-
ily in prevention and treatment of AD.
References
[1] Evans HM, Bishop KS. On the existence of a hitherto unrecognized di-
etary factor essential for reproduction. Science 1922;56:650–1.
[2] Sondergaad E, DamH. Influence of the level of dietary linoleic acid on
the amount of d-alpha-tocopherol acetate required for protection
against encephalomalcia. Z Ernahrungswiss 1966;6:253–8.
[3] Granados H, Dam H. On the histochemical relationship between per-
oxidation and the yellow-brown pigment in the adipose tissue of
vitamin E-deficient rats. Acta Pathol Microbiol Scand 1950;27:591–8.
[4] Harris PL, Embree ND. Quantitative consideration of the effect of
polyunsaturated fatty acid content of the diet upon the requirements
for vitamin E. Am J Clin Nutr 1963;13:385–92.
[5] Wolf G. The discovery of the antioxidant function of vitamin E: the
contribution of Henry A Matill. J Nutr 2005;135:363–6.
[6] TraberMG, Atkinson J. Vitamin E, antioxidant and nothingmore. Free
Radic Biol Med 2007;43:3–15.
[7] Zingg JM. Modulation of signal transduction by vitamin E. Mol
Aspects Med 2007;28:481–506.
[8] Zingg JM, Azzi A. Non antioxidant activities of vitamin E. Curr Med
Chem 2004;11:1113–33.
[9] Roy S, Lado BH, Khanna S, Sen CK. Vitamin E sensitive genes in the
developing rat fetal brain: a high-density oligonucleotide microarray
analysis. FEBS Lett 2002;530:17–23.
[10] Rimbach G, Minihane AM, Majewicz J, Fisher A, Pallauf J, Virgili F,
et al. Regulation of cell signaling by vitamin E. Proc Nutr Soc 2002;
61:415–25.
[11] Kolosova NG, Shcheglova TV, Sergeeva SV, Loskutova LV. Long-term
antioxidant supplementation attenuates oxidative stress markers and
cognitive deficits in senescent-accelerated OXYS rats. Neurobiol
Aging 2006;27:1289–97.
V. Boccardi et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 182-191190[12] Farina N, Isaac MG, Clark AR, Rusted J, Tabet N. Vitamin E for Alz-
heimer’s dementia andmild cognitive impairment. Cochrane Database
Syst Rev 2012;11:CD002854.
[13] Sheppard AJ, Pennington JAT, Weihrauch JL. Analysis and distribu-
tion of vitamin E in vegetable oils and foods. In: Packer L, Fuchs J,
eds. Vitamin E in health and disease. New York: Marcel Dekker,
Inc.; 1993. p. 9–31.
[14] Yap SP, Yuen KH, Wong JW. Pharmacokinetics and bioavailability of
alpha-, gamma and delta-tocotrienols under different food status. J
Pharm Pharmacol 2001;53:67–71.
[15] Mangialasche F, Baglioni M, Cecchetti R, Kivipelto M, Ruggiero C,
Piobbico D, et al. Lymphocytic mitochondrial aconitase activity is
reduced in Alzheimer’s disease and mild cognitive impairment. J Alz-
heimers Dis 2015;44:649–60.
[16] Picco A, Polidori MC, Ferrara M, Cecchetti R, Arnaldi D, Baglioni M,
et al. Plasma antioxidants and brain glucosemetabolism in elderly sub-
jects with cognitive complaints. Eur J Nucl Med Mol Imaging 2014;
41:764–75.
[17] Mangialasche F, Polidori MC, Monastero R, Ercolani S, Camarda C,
Cecchetti R, et al. Biomarkers of oxidative and nitrosative damage
in Alzheimer’s disease and mild cognitive impairment. Ageing Res
Rev 2009;8:8285–305.
[18] Brigelius-Flohe R. Vitamin E: the shrew waiting to be tamed. Free
Radic Biol Med 2009;46:543–54.
[19] M€uller L, Theile K, B€ohm V. In vitro antioxidant activity of tocoph-
erols and tocotrienols and comparison of vitamin E concentration
and lipophilic antioxidant capacity in human plasma. Mol Nutr Food
Res 2010;54:731–42.
[20] Li D, Saldeen T, Romeo F, Mehta JL. Relative effects of a- and g-
tocopherol on low-density lipoprotein oxidation and superoxide dis-
mutase and nitric oxide synthase activity and protein expression in
rats. J Cardiovasc Pharmacol Ther 1999;4:219–26.
[21] Voronkov M, Braithwaite SP, Stock JB. Phosphoprotein phosphatase
2A: a novel druggable target for Alzheimer’s disease. Future Med
Chem 2011;3:821–33.
[22] Ahsan H, Ahad A, Iqbal J, Siddiqui WA. Pharmacological potential of
tocotrienols: a review. Nutr Metab (Lond) 2014;11:52.
[23] Gustaw-Rothenberg K, Kowalczuk K, Stryjecka-Zimmer M. Lipids’
peroxidation markers in Alzheimer’s disease and vascular dementia.
Geriatr Gerontol Int 2010;10:161–6.
[24] Grundman M. Vitamin E and Alzheimer disease: the basis for addi-
tional clinical trials. Am J Clin Nutr 2000;71:630S–6.
[25] Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS,
Aggarwal NT, et al. Relation of the tocopherol forms to incident Alz-
heimer disease and to cognitive change. Am J Clin Nutr 2005;
81:508–14.
[26] Hensley K, Barnes LL, Christov A, Tangney C, Honer WG,
Schneider JA, et al. Analysis of postmortem ventricular cerebrospinal
fluid from patients with and without dementia indicates association of
vitamin E with neuritic plaques and specific measures of cognitive per-
formance. J Alzheimers Dis 2011;24:767–74.
[27] Yatin SM, Varadarajan S, Butterfield DA. Vitamin E prevents Alz-
heimer’s amyloid-beta-peptide (1-42)-induced neuronal protein oxida-
tion and reactive oxygen species production. J Alzheimers Dis 2000;
2:123–31.
[28] Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of
inflammation in Alzheimer disease. Nat Rev Neurosci 2015;
16:358–72.
[29] Rota C, Rimbach G, Minihane AM, Stoecklin E, Barella L. Dietary
vitamin E modulates differential gene expression in the rat hippocam-
pus: potential implications for its neuroprotective properties. Nutr
Neurosci 2005;8:21–9.
[30] Gohil K, Schock BC, Chakraborty AA, Terasawa Y, Raber J,
Farese RV, et al. Gene expression profile of oxidant stress and neuro-
degeneration in transgenic mice deficient in alpha-tocopherol transfer
protein. Free Radic Biol Med 2003;35:1343–54.[31] Giraldo E, Lloret A, Fuchsberger T, Vi~na J. Ab and tau toxicities in
Alzheimer’s are linked via oxidative stress-induced p38 activation:
protective role of vitamin E. Redox Biol 2014;2:873–7.
[32] BlockML. NADPH oxidase as a therapeutic target in Alzheimer’s dis-
ease. BMC Neurosci 2008;9:S8.
[33] Chu J, Pratico D. 5-Lipoxygenase as an endogenous modulator of am-
yloid beta formation in vivo. Ann Neurol 2011;69:34–46.
[34] McGreer PL, McGreer EG. NSAIDs and Alzheimer disease: epidemi-
ologic, animal model and clinical studies. Neurobiol Aging 2007;
28:639–47.
[35] Goodwin JS, Goodwin JM, Garry PJ. Association between nutritional
status and cognitive functioning in a healthy elderly population. JAMA
1983;249:2917–21.
[36] Perkins AJ, Hendrie HC, Callahan CM, Gao S, Unverzagt FW, Xu Y,
et al. Association of antioxidants with memory in a multiethnic elderly
sample using the Third National Health and Nutrition Examination
Survey. Am J Epidemiol 1999;150:37–44.
[37] Klapcinska B, Derejczyk J, Wieczorowska-Tobis K, Sobczak A, Sado-
wska-Krepa E, Danch A. Antioxidant defense in centenarians (a pre-
liminary study). Acta Biochim Pol 2000;47:281–92.
[38] Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P,
Cherubini A, et al. Plasma antioxidants are similarly depleted in
mild cognitive impairment and in Alzheimer’s disease. Neurobiol Ag-
ing 2003;24:915–9.
[39] Ortega RM, Requejo AM, Lopez-Sobaler AM, Andres P, Navia B,
Perea JM, et al. Cognitive function in elderly people is influenced by
vitamin E status. J Nutr 2002;132:2065–8.
[40] Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC,
Hofman A, Witteman JC, et al. Dietary intake of antioxidants and
risk of Alzheimer disease. JAMA 2002;287:3223–9.
[41] Cherubini A, Martin A, Andres-Lacueva C, Di Iorio A, Lamponi M,
Mecocci P, et al. Vitamin E levels, cognitive impairment and dementia
in older persons: the InCHIANTI study. Neurobiol Aging 2005;
26:987–94.
[42] Ravaglia G, Forti P, Lucicesare A, Pisacane N, Rietti E,
Mangialasche F, et al. Plasma tocopherols and risk of cognitive impair-
ment in an elderly Italian cohort. Am J Clin Nutr 2008;87:1306–13.
[43] Mangialasche F, Kivipelto M, Mecocci P, Rizzuto D, Palmer K,
Winblad B, et al. High plasma levels of vitamin E forms and reduced
Alzheimer’s disease risk in advanced age. J Alzheimers Dis 2010;
20:1029–37.
[44] Mangialasche F, Xu W, Kivipelto M, Costanzi E, Ercolani S,
Pigliautile M, et al. Tocopherols and tocotrienols plasma levels are
associated with cognitive impairment. Neurobiol Aging 2012;
332:282–90.
[45] Mangialasche F, Westman E, Kivipelto M, Muehlboeck JS,
Cecchetti R, Baglioni M, et al. Classification and prediction of clinical
diagnosis of Alzheimer’s disease based on MRI and plasma measures
of a-/g-tocotrienols and g-tocopherol. J InternMed 2013;273:602–21.
[46] Mangialasche F, Solomon A, Kareholt I, Hooshmand B, Cecchetti R,
Fratiglioni L, et al. Serum levels of vitamin E forms and risk of cogni-
tive impairment in a Finnish cohort of older adults. ExpGerontol 2013;
48:1428–35.
[47] La Rue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ.
Nutritional status and cognitive functioning in a normally aging sam-
ple: a 6-y reassessment. Am J Clin Nutr 1997;65:20–9.
[48] Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Vitamin
E and cognitive decline in older persons. Arch Neurol 2002;
59:1125–32.
[49] Grodstein F, Chen J, Willett WC. High-dose antioxidant supplements
and cognitive function in community-dwelling elderly women. Am J
Clin Nutr 2003;77:975–84.
[50] Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D,
Tschanz JT, et al. Reduced risk of Alzheimer disease in users of anti-
oxidant vitamin supplements: the Cache County Study. Arch Neurol
2004;61:82–8.
V. Boccardi et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 182-191 191[51] Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K,
Grundman M, et al. A controlled trial of selegiline, alpha-
tocopherol, or both as treatment for Alzheimer’s disease. N Engl J
Med 1997;336:1216–22.
[52] Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R,
Ferris S, et al. Vitamin E and donepezil for the treatment of mild cogni-
tive impairment. N Engl J Med 2005;352:2379–88.
[53] Kang JH, Cook N, Manson J, Buring JE, Grodstein FA. Randomized
trial of vitamin E supplementation and cognitive function in women.
Arch Intern Med 2006;166:2462–8.
[54] Lloret A, Badıa MC, Mora NJ, Pallardo FV, Alonso MD, Vi~na J.
Vitamin E paradox in Alzheimer’s disease: it does not prevent loss
of cognition and may even be detrimental. J Alzheimers Dis 2009;
17:143–9.
[55] Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M,
et al. Effect of vitamin E and memantine on functional decline in Alz-
heimer disease: the TEAM-AD VA cooperative randomized trial.
JAMA 2014;311:33–44.
[56] Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ,
Guallar E. Meta-analysis: high-dosage vitamin E supplementation
may increase all-cause mortality. Ann Intern Med 2005;142:37–46.[57] Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C.Mortal-
ity in randomized trials of antioxidant supplements for primary and
secondary prevention: systematic review and metaanalysis. JAMA
2007;297:842–57.
[58] Frank J, Chin XWD, Schrader C, Eckert GP, Rimbach G. Do tocotrie-
nols have potential as neuroprotective dietary factors? Ageing Res Rev
2012;11:163–80.
[59] Podszun M, Frank J. Vitamin E-drug interactions: molecular basis and
clinical relevance. Nutr Res Rev 2014;16:1–17.
[60] Serbinova E, Kagan V, Han D, Packer L. Free radical recycling and in-
tramembrane mobility in the antioxidant properties of alpha-
tocopherol and alpha-tocotrienol. Free Radic Biol Med 1991;
10:263–75.
[61] Suzuki YJ, Tsuchiya M, Wassall SR, Choo YM, Govil G, Kagan VE,
et al. Structural and dynamicmembrane properties of alpha-tocopherol
and alpha-tocotrienol: implication to themolecularmechanism of their
antioxidant potency. Biochemistry 1993;32:10692–9.
[62] Corbett A, Ballard C. The value of vitamin E as a treatment for Alz-
heimer’s disease remains unproven despite functional improvement,
due to a lack of established effect on cognition or other outcomes
from RCTs. Evid Based Med 2014;19:140.
